Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report

Entrectinib, a ROS‐1 inhibitor, has been shown to be effective for patients with ROS‐1 fused NSCLC, and has been established as the standard of care for this population. Entrectinib has been shown to achieve a better response to brain metastasis due to the characteristic of the drug having a weak in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Kentaro, Nishio, Miho, Fujiwara, Kentaro, Nishii, Yoichi, Ushiro, Kengo, Yasui, Hiroki, Hataji, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481142/
https://www.ncbi.nlm.nih.gov/pubmed/37544307
http://dx.doi.org/10.1111/1759-7714.15044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481142/
https://www.ncbi.nlm.nih.gov/pubmed/37544307
http://dx.doi.org/10.1111/1759-7714.15044

Ejemplares similares